Background: Despite its widespread use, the semi-quantitative standardized uptake value ratio (SUVR) may be biased compared with the distribution volume ratio (DVR). This bias may be partially explained by changes in cerebral blood flow (CBF) and is likely to be also dependent on the extent of the underlying amyloid-β (Aβ) burden. This study aimed to compare SUVR with DVR and to evaluate the effects of underlying Aβ burden and CBF on bias in SUVR in mainly cognitively unimpaired participants. Participants were scanned according to a dual-time window protocol, with either [F]flutemetamol (N = 90) or [F]florbetaben (N = 31). The validated basisfunction-based implementation of the two-step simplified reference tissue model was used to derive DVR and R parametric images, and SUVR was calculated from 90 to 110 min post-injection, all with the cerebellar grey matter as reference tissue. First, linear regression and Bland-Altman analyses were used to compare (regional) SUVR with DVR. Then, generalized linear models were applied to evaluate whether (bias in) SUVR relative to DVR could be explained by R for the global cortical average (GCA), precuneus, posterior cingulate, and orbitofrontal region.
Results: Despite high correlations (GCA: R ≥ 0.85), large overestimation and proportional bias of SUVR relative to DVR was observed. Negative associations were observed between both SUVR or SUVR and R albeit non-significant.
Conclusion: The present findings demonstrate that bias in SUVR relative to DVR is strongly related to underlying Aβ burden. Furthermore, in a cohort consisting mainly of cognitively unimpaired individuals, the effect of relative CBF on bias in SUVR appears limited. EudraCT Number: 2018-002277-22, registered on: 25-06-2018.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098761 | PMC |
http://dx.doi.org/10.1186/s13550-022-00898-8 | DOI Listing |
Alzheimers Dement
December 2024
Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, USA.
Background: The spread of tau in Alzheimer's Disease (AD) can be tracked in vivo using [F-18]MK6240, a PET radioligand that binds to tau aggregates in AD with high affinity. However, significant MK6240 signal is also observed in the meninges and sinus and the extra cerebral binding (ECB) signal from these regions can spill into exterior brain regions complicating evaluation of early stage AD tauopathy. This study evaluates the magnitude and variability of ECB in a large imaging cohort to identify trends in this signal.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
CSIRO Health and Biosecurity, Australian E-Health Research Centre, Parkville, VIC, Australia.
Background: PET quantification using the Standardised Uptake Value Ratio (SUVR) relies on the availability of a robust reference region. Intrinsic noise, spill in, and specific binding in the reference region can impact the reliability of the resulting SUVR. We evaluate a novel deep learning method trained on longitudinal data that penalises unexpected temporal changes and learns a SUVR correction factor that compensates for any noise or bias in the reference region, resulting in an improved quantification.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Erasmus University Medical Center, Rotterdam, Netherlands.
Background: Arteriosclerosis is linked to an increased risk of dementia and Alzheimer's disease. However, the underlying pathological mechanisms remain unclear. We investigated the association between intracranial arteriosclerosis and cerebral Amyloid beta (Aß).
View Article and Find Full Text PDFBackground: Tau phosphorylated at threonine 217 (pTau217) is one of the most promising blood-based biomarkers of Alzheimer's disease (AD). This study compares the performance of two plasma pTau217 immunoassays on the Simoa platform for detection of abnormal amyloid-PET.
Method: Plasma samples from 112 individuals without cognitive impairment and 114 with mild cognitive impairment (MCI) or AD related dementia were evaluated.
Alzheimers Dement
December 2024
NYU Alzheimer's Disease Research Center, New York, NY, USA.
Background: Assessment of anti-amyloid therapies for Alzheimer's disease (AD) requires understanding racial differences in brain amyloid. We compared amyloid burden in non-Hispanic Black/African American and White (NHB, NHW) adults in a cohort with over 40% NHB participants and explored factors associated with the inter-group differences.
Method: We included consecutive non-Hispanic participants who underwent brain amyloid PET-MRI exams in 2021-2023 at NYU Alzheimer's Disease Research Center.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!